Related Experiment Videos
Peritoneal dialysis: new developments and new problems
C W Gradden1, R Ahmad, G M Bell
1Renal Unit, Royal Liverpool University Hospital Trust, Liverpool, UK. farndon@freeuk.com
Summary
Icodextrin-based peritoneal dialysis (PD) can lead to hyponatraemia (low sodium), particularly in diabetic patients. This risk factor may cause serious symptoms when combined with other health issues.
Area of Science:
- Nephrology
- Endocrinology
- Internal Medicine
Background:
- Hyponatraemia is a common complication in patients undergoing dialysis.
- Icodextrin is a commonly used osmotic agent in peritoneal dialysis solutions.
- The impact of icodextrin on sodium levels, especially in diabetic patients, requires further investigation.
Purpose of the Study:
- To determine the incidence of hyponatraemia in patients on peritoneal dialysis (PD).
- To assess the effect of icodextrin-based PD solutions on hyponatraemia in diabetic and non-diabetic individuals.
Main Methods:
- Retrospective analysis of PD patient data, including plasma sodium, albumin, and renal function.
- Comparison of patients using icodextrin-based solutions versus dextrose-based solutions.
- Statistical analysis using the paired Student's t-test.
Main Results:
- Patients on icodextrin-based PD exhibited significantly lower plasma sodium levels compared to those on dextrose-based solutions.
- Plasma sodium levels decreased in all patients after initiating icodextrin-based PD.
- The decline in plasma sodium was statistically significant in both diabetic and non-diabetic patients, falling below reference ranges primarily in diabetic patients.
Conclusions:
- Icodextrin-based peritoneal dialysis is identified as a risk factor for developing hyponatraemia.
- Clinically significant symptoms may arise if hyponatraemia is exacerbated by other patient-specific factors.